[Allogeneic hematopoietic stem cell transplantation from HLA-matched donor for 14 patients with myelodysplastic syndrome].

Abstract

The aim of this study was to explore the feasibility and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of patients with myelodysplastic syndrome (MDS). 14 patients with MDS were treated with allo-HSCT, out of them 9 patients received hematopoietic stem cell transplantation from related donors, while 5 donors were unrelated. 1 patient received bone marrow transplantation and other 13 patients received peripheral blood hematopoietic stem cell transplantation. The modified BU/CY conditioning regimen was used in 11 patients, TBI+CY in 2 patients and reduced intensity FB conditioning regimen in 1 patient. CsA + MTX + MMF were used for graft-versus-host disease (GVHD) prophylaxis. Patients with allo-HSCT from unrelated donors or HLA-mismatched donors received rabbit anti-T-lymphocyte globulin (ATG). The results showed that 12 ALL patients successfully reconstructed their haematopoietic system. The time from transplantation to ANC > 1.0 x 10(9)/L and Plt > 50 x 10(9)/L were 12 (11 - 16) days and 13 (11 - 19) day after transplantation respectively. 11 patients survival free disease and their longest survival time had been up to 125 months. 1 case died early because of cerebral hemorrhage. 1 case died at 66 day because of aGVHD IV, alimentary tract hemorrhage and multiple organ failure.1 case relapsed at 8 months and died of marrow failure at 17 months. Over survival (OS) rate was 78.6% and disease free survival (DFS) was 84.6%. The main complications were aGVHD of I-II grade in 6 cases. It is concluded that allo-HSCT is a safe and effective option for the patients with MDS.

• Authors: Ying Zhou, Wen-Rong Huang, Hong-Hua Li, Chun-Ji Gao, Li Yu
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 18 Issue 3 Pg. 731-4 (Jun 2010) ISSN: 1009-2137 [Print] China
• PMID: 20561439 (Publication Type: Evaluation Study, Journal Article)

Topics

• Adult
• Disease-Free Survival
• Female
• Graft vs Host Disease
• Hematopoietic Stem Cell Transplantation
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (surgery)
• Treatment Outcome
• Young Adult